Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Thyroglobulin Autoantibodies are Associated With Refractoriness to Antithyroid Drug Treatment for Graves’ Disease
source: Internal Medicine
year: 2016
authors: Katahira M, Ogata H
summary/abstract:Objective:
The recurrence rate associated with antithyroid drug (ATD) treatment for Graves’ disease (GD) is high compared with that for radioiodine therapy or surgery. It is important to identify patients in whom remission is unlikely, so that they are not given treatment that is destined to fail. The objective of this study was thus to evaluate factors influencing the prognosis of GD patients treated with ATDs.
Patients:
One hundred and sixty-one patients were divided into two groups: 100 patients who could not discontinue ATDs for eight years or more (refractory group) and 61 patients who achieved remission within eight years after starting ATD treatment (nonrefractory group). The groups were compared in terms of age, thyroid function and thyroid-related autoantibodies at diagnosis, and the durations to the recovery of thyroid function and thyroid-related autoantibodies.
Results:
The baseline levels of free triiodothyronine (T3), free thyroxine (T4), thyroid-stimulating antibodies (TSAbs) and thyroid-stimulating hormone (TSH) receptor antibodies (TRAbs) were high, and the age at diagnosis and the baseline level of thyroglobulin autoantibodies (TgAbs) were low in the refractory group compared with those in the nonrefractory group. The durations to the recovery of TSH, free T4, TRAb and TSAb levels were longer in the refractory group than in the nonrefractory group. No significant difference was observed with regard to thyroid peroxidase autoantibodies.
Conclusion:
We compared the clinical features of these two groups in order to identify factors influencing the prognosis of GD patients treated with ATDs. A low baseline level of TgAbs is associated with the refractoriness of GD to ATD treatment.
DOI: 10.2169/internalmedicine.55.6095
read more
myBinderRelated Content
-
GDATF Community Conversations: Long-Term Use of Anti-Thyroid Drugshttps://www.youtube.com/watch?v=Az5B8FU7...
-
Most Patients With Graves’ Disease Treated With Antithyroid Drugs Eventually Require Additional TherapiesGraves’ disease is the most common cau...
-
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ D...Over-activity of the thyroid gland, call...
-
Substituting Potassium Iodide for Methimazole as the Treatment for Graves’ Disease During the First Trimester ...Background: To control hyperthyroidism ...
-
Recurrence of Graves’ Disease is Predicted by Lower Patient Age at Initial Diagnosis: Implications for CareOne of the greatest challenges in managi...
-
Graves’ Disease and Pregnancy PlanningBoth hypothyroidism and hyperthyroidism ...
-
A 6-Year Follow-Up of a Randomized Prospective Trial Comparing Methimazole Treatment With or Without Exogenous L-Thy...Objective: Antithyroid drug therapy is ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
Facebook
Google